ALK and hepatocellular carcinoma: Oxaliplatin is a standard treatment option for HCC [41], and LDK-378, a prospective inhibitor of anaplastic lymphoma kinase [68], was shown to promote apoptosis and suppress the proliferation of HCC cells [69].